1. Home
  2. MD vs NRIX Comparison

MD vs NRIX Comparison

Compare MD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$21.84

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
NRIX
Founded
1979
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
MD
NRIX
Price
$21.84
$18.81
Analyst Decision
Hold
Strong Buy
Analyst Count
4
13
Target Price
$21.00
$27.46
AVG Volume (30 Days)
973.9K
1.9M
Earning Date
02-19-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.91
N/A
Revenue
$1,922,442,000.00
$83,687,000.00
Revenue This Year
N/A
$59.40
Revenue Next Year
$2.70
N/A
P/E Ratio
$11.47
N/A
Revenue Growth
N/A
48.32
52 Week Low
$11.84
$8.18
52 Week High
$24.99
$22.50

Technical Indicators

Market Signals
Indicator
MD
NRIX
Relative Strength Index (RSI) 48.38 57.98
Support Level $21.35 $18.79
Resistance Level $22.19 $19.54
Average True Range (ATR) 0.58 0.88
MACD -0.13 -0.22
Stochastic Oscillator 33.69 53.61

Price Performance

Historical Comparison
MD
NRIX

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: